GlaxoSmithKline plc Sponsored ADR(GSK.US)RSV vaccine receives FDA expanded approval, adding 21 million adult market to compete with Pfizer Inc.

GlaxoSmithKline plc Sponsored ADR (GSK.US) developed the Arexvy vaccine for the prevention of respiratory syncytial virus (RSV), which was granted expanded approval by US regulators on March 13th (Friday). The approval now includes coverage for all high-risk adult populations. Given that the Trump administration is strengthening the review of vaccine-related issues, this news is undoubtedly a "confidence booster" for pharmaceutical companies. This vaccine had previously been approved by the US Food and Drug Administration (FDA) for all adults aged 60 and older, as well as for those aged 50 to 59 who have at least one high-risk disease. The new approval will add approximately 21 million adults in the US who meet the criteria for vaccination, allowing the Arexvy vaccine to compete with similar vaccines from Pfizer Inc. (PFE.US) in the market. RSV is a highly dangerous virus that can be fatal, posing a serious threat to infants and the elderly. In the US alone, tens of thousands of people are hospitalized each year due to RSV infections. Approximately 17,000 adults aged 18 to 49 are hospitalized in the US each year due to RSV infections. This vaccine developed by GlaxoSmithKline plc with adjuvant components provided by Agenus aims to enhance the immune response in the human body. For vaccine supporters, this approval decision is a significant advantage. Previously, senior health officials in the Trump administration had criticized vaccine administration and raised standards and thresholds for future vaccine approvals. It is worth mentioning that the former head of the FDA's vaccine division, Vaneet Prasad, announced his resignation next month, ending his turbulent second term. This approval decision comes just one week after his announcement. The approval of this vaccine was based on a study with less than 1,000 participants. The study found that the immune response to this vaccine in the 50-59 age group was comparable to that in the over 60 age group already approved for vaccination. Additionally, 600 people were monitored to ensure the safety of the vaccine. Next, the US Advisory Committee on Immunization Practices (ACIP) will consider whether to include the 50-59 age group in the recommended vaccination range for Arexvy. This committee plays a crucial role in determining whether the vaccine will be covered by insurance. They previously voted to expand the recommendation for RSV vaccination to adults aged 50-59. However, the committee has not yet made a decision on whether repeat vaccinations are recommended, leading to uncertainty in the vaccine market due to the prospect of repeat vaccinations. The committee will hold a meeting next week, but it has not yet indicated when it may consider expanding the recommended range for RSV vaccination. It is important to note that this "expansion" refers to the expansion of the recommended range for repeat vaccinations, not the expansion of the age range for vaccination.